Pfizer, Inc. announced that the US FDA approved CIBINQO® (abrocitinib), an oral, once-daily, Janus kinase 1 inhibitor, for the treatment of adults living with refractory, moderate-to-severe atopic dermatitis.
[Pfizer, Inc.]
Sorry, but the selected Zotpress account can't be found.